Online / Physical Event

13th Edition of International Conference on

Nanomedicine and Advanced Drug Delivery

Theme: Nano-pharmaceutics and Drug Delivery: Challenges and Breakthroughs

Event Date & Time

Event Location

London, UK

Brochure Program Abstract Registration ReaderBase Awards

20 Years Of Excellence in Scientific Events


Performers / Professionals From Around The Globe

Conference Speaker


GAMA Healthcare Ltd

Conference Speaker


University of Queensland

Conference Speaker


GAMA Healthcare Ltd.

Conference Speaker


Department of Biosensors

Conference Speaker


university of Strathclyde

Conference Speaker

samaneh kabirian dehkordi

University of Lyon

Conference Speaker

Rongjun Chen

Imperial College

Conference Speaker

Patrick Sinko

Rutgers University

Conference Speaker

Sergey Suchkov

Sechenov University

Conference Speaker


University of Greenwich

Conference Speaker


University of Greenwich

Conference Speaker


Princeton University

Tracks & Key Topics

Nano Drug Delivery 2019


EuroSciCon invites all the participants from all over the world to attend International Conference on Nanomedicine and Advanced Drug Delivery which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

It is forecasted that the total market size of Nanomedicine and Advanced Drug Delivery would be $755.3 billion with a 60/40 split between nanomedicine and advanced drug delivery respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

Nanomedicine and drug delivery can address one of the greatest difficulties in the post-genomic time of the 21st century – making the essential associations amongst Academics and industry professional.

To address these difficulties, the field of Nanomedicine and advanced drug delivery has experienced exponential development amid the last 5 years. Innovations, for example, Personalized NanomedicineDesign of NanodrugsDrug targeting and designRoutes of drug administrationNovel and Smart drug delivery systemRegenerative Medicine and Tissue EngineeringNanotechnology and Biomedical applications, Nanomaterials for Drug Delivery, Regulatory Aspects Towards Approval of Nanomedicine, Application of nanotechnology for treatment of cancer etc., Nano Pharmaceutical Industry and Market processing and drug delivery guarantee to change the world of nanopharmaceutics and advanced drug delivery system much similar way that integrated and changed the world of pharmaceutical sciences.

There is a strong market for nanopharmaceutics and drug delivery in Europe. The pharmaceutical business in Ireland is profoundly best in class, incorporating the most recent innovation, cutting edge equipment and strict quality control methodology. Ireland's pharmaceutical industry offers an extensive variety of items and services, from research and development for new medicines to the manufacturing and marketing of new medicines for humans and animals. Around 120 abroad organizations have plants in Ireland including 9 of the 10 biggest pharmaceutical organizations on the planet. The pharmaceutical business is generally new to the Irish economy. A large portion of the organizations working around there have just had nearness in Ireland since the 1960s.

The Pharmaceutical sector had 46.9% growth which is the second biggest percentage increase in NSV in Ireland between the years 2013 – 2016. The most significant increase in Net Selling Value was in the Pharmaceutical sector. The value of Basic pharmaceutical products and preparations increased by 18.2% from €36.1 billion in 2014 to €42.6 billion in 2015. The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market is segmented based on route of administration, facility of use, and region. The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.


Why exhibit?

  • Make sales
  • Debut new product
  • Profile your brand
  • Meet new business partners and suppliers
  • Develop key relationships and Educate healthcare
  • Pharma and biotech institutions and academia.

Who you will meet?

Chance to meet Leaders in

  • Drug Delivery
  • Formulation
  • Drug Development
  • Nanotechnology
  • QbD
  • Delivery Devices
  • Bioavailability
  • New Products
  • Pre-Formulation
  • Process R&D
  • CMC
  • Stability
  • Bio manufacturing
  • Manufacturing
  • Solid State Chemistry
  • Analytical Development
  • Product Enhancement

Who should sponsor?

  • Analytical Services
  • Formulation Development
  • CMO
  • Drug Delivery Technologies
  • Full service CRO
  • Preformulation testing
  • Software

Why you should attend?

  • Get to the heart of why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions.
  • Discover how advances in the sector are impacting both large and small molecule drugs.
  • Explore tried and tested routes to improve bioavailability.
  • Understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set.
  • Discover the latest innovations in drug delivery devices.
  • Be inspired by innovative case studies and realise the potential impact on your formulation or delivery processes.
  • Engage in the exciting event format, with round tables, panels, showcases, speed networking and multiple conference tracks.
  • Share experiences, insights and strategies in interactive peer-to peer round tables.
  • Hear more perspectives in one place – from large medium and small organisations from pharma, biotech and academia.
  • Discover how scientific formulation advancements are being implemented in practice.
  • Get to the heart of why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions.


Track 01: Cancer and Nanotechnology

Nanotechnology can possibly build the selectivity and power of concoction, physical, and organic methodologies for inspiring disease cell demise while limiting collateral toxicity to non-malignant cells. Materials on the nanoscale are progressively being focused to malignancy cells with extraordinary specificity through both active and passive targeting. Customary chemotherapeutics have some genuine reactions including harm of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, absence of solvency, and failure to enter the centre of the tumours bringing about weakened treatment with decreased dosage and with low survival rate. Nanotechnology can provide rapid and sensitive detection of cancer-related targets, enabling scientists to detect molecular changes even when they occur only in a small percentage of cells. Nanotechnology also has the potential to generate unique and highly effective theraputic agents.

Nanotechnology conferences in UK

Track 02: Nanomedicine

Nanomedicine is a branch of medicine that uses the Nanotechnology for the prevention and treatment of disease in the human body. This evolving discipline has the potential to dramatically change medical science. Nanomedicine fuses the usage of nanoscale materials, for instance, biocompatible nanoparticles and nanorobots, for examination, conveyance, distinguishing or incitation purposes in a living structure. Current issues for nanomedicine incorporate understanding the issues related to lethality and environmental impact of nanoscale materials , Preparation of nano-prescriptions and its application. Research are being completed give a wide audit of magnetic nanoparticle, Silver nanoparticles, Gold nanoparticles explore with a special focus on the synthesis, functionalization and medicinal uses of these particles.


Nanomedicine conferences in USA

Track 03: Design of Nanodrugs

Nanodrugs sensational advances in nanotechnology and nanoscience have been joined by energizing advancement in de novo design of nano sized drugs. Nanoparticles with their vast space of structural amenability and phenomenal mechanical and electrical properties have turned out to be perfect contender for high viability nanomedicines in both diagnostics and therapeutics. The restorative nanomedicines can be additionally sorted into nanoparticle drug delivery for regular medications and nanodrugs and nanobots with coordinate curing of target illnesses. Nano molecule are characterized into three general classifications One dimension, two dimension , and three dimension nanoparticles and each have an different fabrication techniques. Difficulties in design of nano drugs incorporate system of drug loading and discharge, safety issues and its limitations and so on.

Nanodrugs conferences in Ireland

Track 04: Drug Targeting and Design

The main objective in drug design is to foresee whether a given particle will bind to a target and if so how unequivocally. Molecular mechanics or molecular dynamics are regularly used to predict the conformation of the little particle and to model conformational changes in the biological targets that may happen when the little molecules ties to it. The remedial reaction of a drug relies on the cooperation of drug molecules with cell on cell membrane related biological events at receptor sites in concentration dependent manner.

Drug Design conferences in Australia

Track 05: Novel Drug Delivery Systems

Drug delivery is the way toward managing the drug or pharmaceutical product, so as to accomplish sought therapeutic impact. The strategy by drug delivered is critical, as it has noteworthy impact on its efficacy. Novel drug delivery system (NDDS) includes consolidating polymer science, pharmaceutics and molecular biology. Novel drug delivery systems are outlined in view of physical and biochemical mechanisms. Physical mechanisms or controlled drug delivery system incorporates dissolution, osmosis, and diffusion and so on. Biochemical mechanism incorporates gene therapy, liposomes, nanoparticles, monoclonal antibodies, microemulsions and so forth some example of drug delivery system (DDS) are Transmucosal, Sonophoresis , Lymphoid, Insitu, Micelle, Emulgel, and Hydrogel drug delivery system (DDS).

Novel Drug Delivery Systems conferences in Europe

Track 06: Routes of Drug Administration

Route of administration in medicine is the path by which a drug is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Routes of drug administration is aimed at developing novel routes to minimize side effects form common routes by which a drug is brought into contact with the body.

The drug delivery technology market is expected to reach USD 1,504.7 Billion by 2020 from USD 1,048.1 Billion in 2015, growing at a CAGR of 7.5% from 2015 to 2020. Factors such as rising prevalence of chronic diseases, growth of the biologics market, new product launches, and drug innovation and technological advancements are driving the growth of this market. On the other hand, patent expiry and patent cliff, increase in the injuries and side effects are hindering the growth of this market.

Drug Administration conferences in China

Track 07: Pharmaceutical Nanotechnology

Nanotechnology has turned into a fundamental component of pharmaceutical sciences and finds numerous applications in pharmaceutical formulation design and drug delivery systems in upgrading helpful execution of medications. A significant number of the current "nano" medicate conveyance frameworks are family of regular measurements shapes like nanosuspensions, nanoemulsions, and nanomicelles Pharmaceutical Nanotechnology manages rising new innovations for creating redid answers for drug delivery systems. The medication conveyance framework emphatically impacts the rate of ingestion, dispersion, digestion, and discharge of the medication or other related compound substances in the body. Notwithstanding this the medication conveyance framework additionally enables the medication to tie to its objective receptor and impact that receptor's signaling and activity.

Pharmaceutical Nanotechnology conferences in UK

Track 08: Nanomaterials for Drug Delivery

Nanomaterials vary fundamentally from different materials because of the accompanying two noteworthy primary factors: the expanded surface zone and quantum impacts. These elements can improve properties, for example, reactivity, quality, electrical characteristics and in vivo behaviour. Nanotechnology and nanoscience are generally observed as having an awesome potential to bring advantages to numerous ranges of research and applications. The utilization of nanotechnology in the field of medicinal services has gone under awesome consideration as of late. There are numerous medications today that take a considerable measure of time and are additionally exceptionally costly. Utilizing nanotechnology, snappier and considerably less expensive medications can be created , the real difficulties in these medication delivery is the choice of sheltered and biocompatible nanocarriers , mechanism for drug delivery, solubilisation procedures.

Nanomaterials conferences in Italy

Track 09: Nanotechnology and Biomedical Applications

The applications of technology in drugs and biomedical engineering are huge and spans areas like implant and tissue engineering, diagnosis , Bio-Sensors , nano-probes and medical aid .There is another viewpoint for utilizing technology. Ordinarily, medicine run through the complete body before they achieve the sickness influenced region. Utilizing nanotechnology, the medication can be focused to an exact area which would make the medication considerably more successful and decrease the odds of conceivable symptoms. Nanotechnology also finds its application in dentistry , biosystems , respiratory diseases , Genetic nanomedicine etc.

Nanotechnology and Biomedical conferences in Germany

Track 10: Personalized Nanomedicine

Personalized medicine means to individualize chemotherapeutic intercessions on the basis of ex vivo and in vivo data on patient-and disease-specific characteristics. By noninvasively picturing how well picture guided nanomedicines-that is, sub-micrometer sized drug delivery systems containing the drugs and imaging operators inside a solitary formulation, and intended to all the more particularly convey drugs particles to pathologic destinations gather at the target site, patients prone to react to nanomedicine-based therapeutic interventions might be preselected. What's more, by longitudinally observing how well patients react to nanomedicine-based therapeutic mediations, tranquilize measurements and treatment protocols can be individualized and improved amid development.

Nanomedicine conferences in China

Track 11: Drug Delivery Research

Drug delivery describes the tactic and approach to delivering medicine or and different xenobiotics to their site of action inside an organism, with the goal of achieving a therapeutic outcome. problems with pharmacodynamics and pharmacokinetics area necessary concerns for drug delivery. Designing and developing novel drug delivery systems, with attention on their application to sickness conditions. diagnosis and clinical knowledge associated with drug delivery systems. Drug distribution, pharmacokinetics , clearance, with drug delivery systems as compared to ancient dosing to demonstrate helpful outcomes. short and long biocompatibility of drug delivery systems, host response. Biomaterials with growth factors for stem-cell differentiation in regenerative medication and tissue engineering. Devices for drug delivery and drug/device combination product.

Drug Delivery conferences in Europe

Track 12: Drug Delivery Equipment’s and Machinery

Equipment and Machinery for Drug Delivery incorporates Laboratory equipment's, Analytical equipment's, Auto Injectors, Semi-Automatic, R&D Equipment, Large volume Production Machineries and Drug Delivery Pilot hardware's and so forth this field is progressing at a colossal pace.

The drug delivery technology market is expected to reach USD 1,504.7 Billion by 2020 from USD 1,048.1 Billion in 2015, growing at a CAGR of 7.5% from 2015 to 2020. Factors such as rising prevalence of chronic diseases, growth of the biologics market, new product launches, and drug innovation and technological advancements are driving the growth of this market. On the other hand, patent expiry and patent cliff, increase in the injuries and side effects are hindering the growth of this market.

Drug Delivery conferences in Japan

Track 13: Smart Drug Delivery Technology

With the uncommon advances of biomedical nanotechnology amid the previous couple of decades, customary drug delivery systems (DDSs) have been included into smart DDSs with boosts responsive characteristics. The smart drug delivery system is utilized for conveying drugs to the host. Organic data identified by biological sensors is examined and the drug delivery system is impelled to convey the drugs in view of the data. The framework uses MEMS or NEMS innovation based drugs pumps, micro pumps, miniaturized needles, micro-osmotic pumps, and nano-pumps. MEMS based drug delivery system give improved medication treatment which permits precise dosing with more viability and adequacy. The utilization of MEMS for drug delivery through biocapsules, microneedles, and micropumps offers a less obtrusive drug therapy and enhances the quality life of the patients. It likewise incorporates sensors or communication frameworks to remotely actuate or control the pumps.

Drug Delivery Technology conferences in Italy

Track 14: Regenerative Medicine and Tissue Engineering

Regenerative medicines and tissues engineering, are the branches of biomedical engineering. Tissue engineering and regenerative medicines are involved with the replacement or regeneration of cells, tissues or organs to revive traditional biological function. Tissue engineering could be a aggressive space of analysis that aims to make tissue equivalents of blood vessels, heart muscular tissue, nerves, cartilage, bone, and alternative organs for replacement of tissue either broken through sickness or trauma. As an knowledge domain field, principles from biological, chemical, electrical, materials science, and engineering are used in analysis and development.

The global Regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6% from 2016 to 2021. The major factor driving the growth of this market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population.

Tissue Engineering conferences in Australia

Track 15: Regulatory Aspects Towards Approval of Nanomedicine

Biomaterials and nanotechnology are among the most promising tools to conquer drawbacks which were mostly associated with non-specific effects of customary therapeutic approaches. Nonetheless, the extensive use of nanomedicines requests a significant learning and portrayal of these mind boggling items. Their properties should be widely comprehended to keep away from unpredicted consequences for patients, for example potential immune reactivity. Research strategy and organizations together have been uniting researchers, controllers, industry, and, more frequently in recent years, patient representatives and patient support establishments. To effectively upgrade the advancement of new technology , enhanced systems for look into based corporate associations, more coordinated research devices managing suitable translational necessities going for clinical improvement, and proactive administrative arrangements are fundamental sooner rather than later.

Regulatory Aspects conferences in Denmark

Track 16: Vaccine Design and Delivery Technology

Vaccines have long been used to fight against infectious disease; however the last decade has witnessed a revolution in the approach to vaccine design and development. Immunization Drug Delivery are multidisciplinary scientific field that is right now experiencing quick improvement. Latest vaccines that are steady, sparing, require less dosages and can be controlled utilizing needle free frameworks are an overall need. A perfect hypothetical vaccines may not be cogent unless formulated and delivered relevantly. Critical to the accomplishment of a vaccine is the conveyance technique that will be utilized. Currently, various techniques involving DNA vaccines, adjuvants, microparticles and transgenic plants are being developed and evaluated , there has been an increasing emphasis in the field of vaccines on the neeed for improved safety along with improved efficacy against particularly insidious pathogens. More recently , the threats of a bio-terrorist attacks has been added an even sense of urgency to these efforts.

The drug delivery technology market is expected to reach USD 1,504.7 Billion by 2020 from USD 1,048.1 Billion in 2015, growing at a CAGR of 7.5% from 2015 to 2020

Vaccine Design and Delivery Technology conferences in USA

Track 17: Drug Delivery and Device Development

The use of therapeutic devices and different strategies of drug delivery continues to evolve and increase. Drug delivery devices are specialised tools for the delivery of a drug or therapeutic agent via a selected route of administration. Such devices are used as a part of one or a lot of medical treatments .There are many medical devices designed for drug delivery through the respiratory organ and nasal routes. These routes are of interest for native delivery, as in asthma attack, however additionally for speedy delivery of medication to the system circulation and direct delivery to the central nervous system.

Drug Delivery and Development conferences in UK

Track 18: Recent Advances in Drug Delivery

Simplicity of drug administration, safety, affordability and effectiveness are the most important issues in pharmacotherapy resulting in exploration of higher drug delivery systems. Drug targeting to specific organs and tissues has become one in all the essential endeavors of the century since the utilization of drugs in standard dosage forms typically involves difficulties in achieving the target site at the acceptable dose during or after a definite time. Consequently, the look for new drug delivery approaches and new modes of action represent one of the frontier research areas. New drug delivery systems incorporates lipidic, proteic and polymeric technologies to produce new sustained drug delivery with higher body distribution, drug protection from harsh external surroundings and avoidance of drug clearance. several of these technologies have reached the market thus proving the advantages of those new carriers.

Track 19: Major Challenges in Drug Delivery

There are numerous biochemical boundaries that can upset effective drug delivery, Major Challenges in Drug Delivery Systems incorporates delivery of ineffectively dissolvable drugs and bioavailability obstacles for inadequately solvent clinical applicants, protein drug delivery, paediatric and geriatric drug deliverySelf-emulsifying drug delivery system (SEDDS) have unparalleled potential in enhancing oral bioavailability of poorly water-soluble drugs. There are a few Novel methodologies in the delivery, Overcoming bioavailability obstacles and Rationale formulation design of poorly soluble drugs. There is an expanding interest for for effective and, ideally, non-invasive drug-delivery methods.

Today, biopharmaceuticals generate global revenues of $163 billion, making up about 20 percent of the pharma market. It’s by far the fastest-growing part of the industry: biopharma’s current annual growth rate of more than 8 percent is double that of conventional pharma, and growth is expected to continue at that rate for the foreseeable future.

Track 20: Drug Delivery Companies and Markets

Increase in chronic diseases, increasing demand for biologics, advancement of technology , and new product launches are one of the key factors driving the evolution of the drug delivery technology market. moreover, self-administration and residential care and increasing demand for biosimilars and generic medicine supply vital growth opportunities for player operative within the market. On the other hand, risk of needle-stick injuries and side effects of medication might restraint the expansion of the market.

The global revenue for advanced drug delivery systems is estimated to be $151.3 billion in 2013. In 2018, revenues are estimated to reach nearly $173.8 billion, demonstrating a compound annual growth rate (CAGR) of 2.8%.

Prominent players in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), Novartis AG (Switzerland), 3M Company (U.S.), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Sanofi (France), and Antares Pharma, Inc. (U.S.).

Track 21: Nano Pharmaceutical Industry and Market

Nanopharmaceuticals represent an emerging field and offer the capacity to distinguish sicknesses at considerably prior stages and the diagnostic applications could expand upon conventional techniques utilizing nanoparticles, Nano-empowered medical items have had their effect on the areas, for example, cancer, CNS diseases, cardiovascular diseases, and infection control. While nano-upgraded drug delivery items are now a business reality, more progressed nanotech-based medical gadgets are still being developed, although some are at the clinical testing stage. A large portion of the money being spent on the more extensive field of nanotechnology R&D originates from government and built up enterprises. In the nanomedicine field, pharmaceutical and specialist organizations are at the front line of research into the therapeutic uses of nanotechnology.

The global nanomedicine market reached $43.2 billion in 2010 and $50.1 billion in 2011. The market is expected to grow to $107.6 billion by 2016 and is expected to reach 130bn in 2019 at a compound annual growth rate (CAGR) of 14.1.

Nano Pharmaceutical conferences in Europe



Europe, situated toward the west of the United Kingdom. An obvious, development of 26.3% in 2015 has been credited to tax inversion practices by multinationals taking advantage Ireland's low corporate expense rate ("leprechaun financial matters"). Starting at 2015, Ireland was positioned as the world's ninth most "economically free" economy in a record made by free-market economists from the Wall Street Journal and Heritage Foundation, the Index of Economic Freedom.

The Medical technology (MedTech) sector employs nearly 25,000 people and generates 9.4 billion euro annually, with over one hundred companies in the country. The pharmaceutical sector employs approximately 50,000 people and is responsible for 55 billion euro of exports.

They have a globally significant life sciences sector with 8 of the top 10 pharmaceutical companies having major operations there. It generates over 50% of Ireland's exports, making them one of the largest net exporters of medicines in the world

There are 160 medical technology companies in Ireland, with 11 of the top 12 medical technology companies having significant manufacturing or R&D operations in Ireland. This sector employs over 24,000 people and is responsible for 8% of Ireland's total merchandise exports.


The approach of nanotechnology and its application in early finding of ailments, preventive intervention, and prophylaxis of unending and acute disorders is required to fill in as a fillip for nanomedicine market. Nanotechnology includes the scaling down of bigger structures and chemicals to a nanometric scale. Finish improvement and commercialization of the strategies that are relied upon to essentially revolutionize the administration of drugs, in this way impacting adoption through to 2024. Advancement of novel nanotechnology-based drugs and treatments is driven by the need to create treatments that have less reaction and that are more savvy than conventional therapies, specifically for cancer. As per the WHO factsheet, Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 16 million new case 2017 and 8.8 million cancer-related deaths in 2017, Globally, nearly 1 in 6 deaths is due to cancer.

Global nanomedicine market was valued at $214.2 billion in 2013 and $248.3 billion in 2014. The total market is projected to grow at a compound annual growth rate (CAGR) of 16.3% from 2014 through 2019 and reach $528 billion by 2019.

Use of nanotechnology-based difference reagents for analysis and observing of the impacts of drugs on a phenomenal short timescale is additionally attributive drive development in the coming years. Furthermore, demand for biodegradable implants with longer lifetimes that empower tissue reclamation is expected to impact demand.

Solutions, for example, nanoformulations with activated discharge for tailor-made pharmacokinetics, nanoparticles for neighborhood control of tumor in mix with radiotherapy, and functionalized nanoparticles for focused in-vivo actuation of stem cell production are expected to drive R&D, subsequently bringing about income era in the coming years.

The presence of a few items in clinical and investigative pipeline stages is likewise expected to impact development in the coming years attributable to the commercialization of the concluded results. Out of the distinctive therapeutic products more than 40% are in stage II of clinical improvement and can be required to be marketed by the before half of the coming decade, therefore affecting industrial progress in future.

This technology has likewise watched a noteworthy demand in customized drug and treatment inferable from their capacity to treat patients in light of modified medicines for genetic abnormalities and chronic disorder. Moreover, the characteristic principle of nanomedicine that enables site-specific targeting and free movement across the blood-brain barriers facilitates its usage in diagnostics as well as therapeutics at the mean time. This flexibility related with techniques under development in this market are relied upon to expand R&D investment in research projects in the sector consequently fuelling demand. Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups.


The drug delivery technology market is segmented based on route of administration, facility of use, and region. On the basis of route of administration, the market is segmented into oral, injectable, topical, nasal, ocular, pulmonary, implantable, and transmucosa. The topical drug delivery segment is expected to register the highest CAGR during the forecast period. The high growth in this segment can primarily be attributed to the factors such as convenience and ease of use, ease of dosage, painlessness, noninvasiveness, and enhanced patient compliance. On the basis of facility of use, the market is segmented into the hospitals, ambulatory surgical centers/clinics, home care settings, diagnostic centers, and other facilities of use. In 2016, the hospitals segment is expected to account for the largest share of the market. This can be primarily attributed to advantages such as the significant number of inpatient and outpatient visits in hospitals as compared to other end users and the requirement of large volumes of drugs and their respective delivery devices to cater to the demand of this patient pool.

The global advanced drug delivery marketshould grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.

Major Industries related to Nanopharmaceutics and Drug delivery includes:

  • Johnson & Johnson
  • Pfizer
  • Roche
  • Novartis
  • Merck & Co.
  • Sanofi
  • GlaxoSmithKline
  • Gilead Sciences
  • AbbVie
  • Bayer
  • AstraZeneca
  • Boston Scientific
  • Amgen
  • Teva
  • Eli Lilly
  • Bristol-Myers Squibb
  • Medtronics
  • Elan
  • Cardinal Health
  • Shire    


  • International Pharmaceutical Federation (FIP)
  • European Association of Employed Community Pharmacists in Europe (EPhEU)
  • European Pharmaceutical Union (EPU)
  • Pharmaceutical Group of the European Union (PGEU)
  • American Society for Nanomedicine
  • American Association of Colleges of Pharmacy (AACP)
  • American Pharmacists Association (APhA)
  • American Society of Consultant Pharmacists (ASCP)
  • American Society of Health-System Pharmacists (ASHP)
  • American College of Clinical Pharmacy(ACCP)
  • National Pharmacy Association
  • Pharmaceutical Society of Northern Ireland
  • Royal Pharmaceutical Society (RPS)
  • Pharmaceutical Society of Australia
  • The Pharmacy Guild of Australia
  • Institute for Molecular Manufacturing(IMM)
  • International Association of Nanotechnology (IANT)


Examples of Nano Devices:


Nano robots repairing DNA

Microchip devices for drug delivery

Injectable electronics











University of Washington | Georgetown University | University of FloridaDrexel University Online | University of North Carolina | Temple University | University of the Pacific | University of Minnesota | University of Connecticut | University of Montana | University of Toledo | Rochester Institute of Technology | Nanomedicine Conferences | Durham University | University of Aarhus | Aalborg University | University of Southern Denmark – NanoSYD | University of Copenhagen | University of Utah | University of Arizona | University of Oxford | Pierre and Marie Curie University | Rockefeller University | Invitrogen


University of Strathclyde | University of Surrey | Swansea University | Teesside University | Aalto University | Aarhus University | Barcelona University | University of Cambridge | Wurzburg University | University of Bristol | Cranfield University | University of Glasgow | Lancester University | Nanomedicine Conferences | University of Erlangen-Nurnberg | Politecnico de Milano | Queen’s University Belfast | Rovira I Virgili University | Bangor University | University of Birmingham | Frankfurt University | Freiburg University | Kiel University | Fu Berlin University | Lomonosov Moscow State University | University College London (UCL) | University of Southampton | University College Dublin | Kingston University | University of Bradford | European University Cyprus | University of Groningen | University of Central Lancashire | University of Debrecen |  


Virginia Commonwealth University | South Dakota School of Mines And Technology Saint Francis University | Stevens Institute of Technology | University of California | Los Angeles | California University of PennsylvaniaNorth Carolina State University | University of California | Berkeley | University of North Carolina At Charlotte | University of California Irvine | University of Denver | North Dakota State College of Science | Nanomedicine Conferences | Penn State York | University of North Carolina at Greensboro | Northwestern Polytechnic University | Bucks County Community College | Northwest Missouri State University | Oklahoma State University-Institute of Technology | Lehigh Carbon Community College | Harrisburg University of Science And Technology | Texas State Technical College – Waco | Harper College Rutgers | The State University of New Jersey | Wayne State University | University of New Mexico | Normandale Community College | Penn State Greater Allegheny | Foothill College | University of Connecticut | Penn State Fayette | Eberly Campus | Northampton Community College | Virginia Tech | University of Wisconsin-Stout | University of Basel


University of Tokyo | Kyoto University | Osaka University | National University of Singapore (NUS) | Center of Excellence in Nanotechnology at AIT | College of Nanotechnology at KMITL | University Putra Malaysia | Sri Lanka Institute of Nanotechnology (SLINTEC) | The University of Tokyo | Tokyo Institute of Technology | Indian Institute of Nano Science & Technology | Nanomedicine Conferences | VIT University, India | Indian Institute of Science, Bangalore |IITs | NITs | Nano Science and Technology Consortium


Merck | Sanofi | Roche | Pfizer | Novartis | Bayer | QPS | Biocrates | ThioMatrix | Novo Nordisk A/S | Rhoen Klinikum | Morphosys | Stada Arzneim | Polymun Scientific | SanofiGenzyme | Alexion | Baxter | ChemnovaticCSLBehring | Nanomedicine Conferences | Fujirebio Europe | Galen Limited | Martindale Pharma | Covidien | Freudenberg medical | Affiris | Lonza


Nephroceuticals | Ovation Pharmaceuticals | Aphios | Uluru | SeraCare Life Sciences | Platypus Technologies | Impax Laboratories | Insys Therapeutics | Jones Pharma | KaloBios Pharmaceuticals | Lexicon Pharmaceuticals | Meyer Brothers Drug Company | Keystone Nano | NanoBiotech | Cour Pharmaceuticals | T2 Biosystems |  AparnaBio | Celsense | AuraSense | Arrayit | ApoLife | Pentron Clinical TechnologiesParticle Sciences | NovaBay Pharmaceuticals | Nanomedicine Conferences | Nanosyn | NanoBio Corporation | Foster | Biomet 3i


Columbia Pharmaceuticals | Ultimate Sport Nutrition | Astra Pharmaceuticals | Brunel Laboratoria | Nanomedicine Conferences | Dia-Kure Ltd | Nanomedicine Conferences | Geo Schwulst Laboratories | GM Pharmaceuticals | Hersol Manufacturing Laboratories | Johnson & Johnson | Kyron Laboratories | Merck Generics RSA | Novo Nordisk | Pharma Natura | Pharmacare Ltd | Resmed Pharmaceuticals | S N Pharmaceuticals | Adnano Technologies | AFC | Bilcare | Eris Technologies | Astra Zeneca Pharmaceuticals | Resmed Pharmaceuticals | Servier Laboratories | Embassy Pharmaceuticals | Amalgamated Pharmaceuticals | New S Buys | Afrox Limited | Amka Pharmaceuticals  


Research Associate & Research Scientist - FR&D in Trikona Pharmaceuticals Private Limited | Pharmacist - Pentagon Global Solutions Limited | Nanomedicine Conferences | QA/QC in MSN Laboratories | Sr. Executive/asst. Manager/manager-Pharma Techni in Arihant Innochem Pvt Ltd | Leti HEALTH/Clinatec project developing | The University of Manchester | Tyndall Institute | NovarialsLeidos Biomedical Research | Nanoimmunotech | Aix-Marseille University | ICFO


Nanotechnology in Alzheimer and Cancer | Biomedical Engineering at Tulsa | Bioanalytical Chemist (NCI) | University of Oklahoma | University of Illinois at Urbana-Champaign | University of North Carolina | Pfizer | University of South Florida | Massachusetts General Hospital | Northeastern University | Nanomedicine Conferences | Cedars-Sinai | Sorrento Therapeutics | Nanomedicine Conferences | Massachusetts General Hospital | Morehouse School of Medicine | Brand Manager / Product Executive in Senses pharmaceuticals ltd | Stores Clerk in Aristo Pharmaceuticals Pvt. Ltd. | Area Sales Manager in East West Pharma (Pvt) Ltd


ISTplus | Chinese University of Hong Kong | Quality Assurance in Suven Life Sciences Ltd | Risk Management Plan Manager in Novartis | Associate Global Trial Director in Novartis | Product Manager - Ophthalmology | Nanomedicine Conferences


The Pharmaceutical and Healthcare Sciences Society (PHSS) | Controlled Release Society (CRS) | International Society for Aerosols in Medicine (ISAM) | Applied Pharmaceutical Nanotechnology Society (APN) | Nanomedicine Conferences | International Society for Aerosols in Medicine (ISAM) | The Pharmaceutical and Healthcare Sciences Society (PHSS) | Pharmaceutical Society Of New Zealand | Norwegian Pharmacy Association | National Pharmacy Association | American Association of Colleges of Pharmacy | American Pharmacists Association | American Society for Pharmacy Law | American Society of Consultant Pharmacists | Nanomedicine Conferences | Professional Compounding Centers of America | American College of Clinical Pharmacy | Canadian Society of Hospital Pharmacists | Pakistan Pharmacists Association | Philippine Pharmacists Association | College of Psychiatric and Neurologic Pharmacists American Nano Society | International Association of Nanotechnology (IANT) | IEEE Nanotechnology Council | Institute for Molecular Manufacturing (IMM) | Microscopy Society of America (MSA) | Nano Science and Technology Institute (NSTI) | NanoBusiness Alliance | American Chemistry Council Nanotechnology Panel American Society of Health-System Pharmacists | Professional Compounding Centers of America | Nanomedicine Conferences | Canadian Society of Hospital Pharmacists | Pharmaceutical Association of Mauritius | Pakistan Pharmacists Association | Pharmaceutical Association of Mauritius


What Is Nano Drug Delivery?

Nano-pharmaceuticals are designed to better target drugs towards diseased cells, tissues and organs. Diseased cells tend to have specific features on their surface named biomarkers. The targeted nano-pharmaceuticals contain drugs and selectively recognise and bind to the biomarkers on the cells. The drugs are then released locally, resulting in more effective targeting of the diseased cells. Precise targeting of the drugs can reduce side-effects in other parts of the body. Nano pharmaceuticals may include contrast agents that allow the physician to see the location of the disease (e.g. tumour) on the image of a body scan, for instance with Magnetic Resonance Imaging (MRI), X-Ray Computed Tomography (CT) or Positron Emission Tomography (PET). Furthermore, nanotechnology can help in the design of improved drugs that can be administered more easily to the patient, for instance orally instead of by intravenous injections. It can enable the smooth release of drugs over longer time periods, reducing concentration peaks and variations. Nanotechnology can also provide new methods of delivering promising drugs that are not yet suitable for clinical practice because of problems with delivery.

How are Nano-pharmaceuticals made?

Nanotechnology refers to the science of discovering what happens when you make things that are very, very small. Typically, the new nanomaterials and nanodevices being developed are measured in nanometers. One nanometer is one-billionth of a meter. To put that scale in context, the comparative size of a nanometer to a meter is the same as a marble is to the size of the earth.


Media Partners/Collaborator

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker


A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Talk to Us

Speak directly to one of our conference representatives by calling.

+0044-2033180199 +44 8000 148923

Mail Us

E-mail us your questions about the conference. We will respond to your questions.

[email protected]

Contact Us

Have questions?
We'll be in touch within 24 hours.

Contact Us


EuroSciCon Ltd
35 Ruddlesway,
Windsor, Berkshire,

EuroSciCon Events are produced by Euroscicon Ltd

EuroSciCon, founded in 2001 is a UK based independent life science Events Company with predominantly business and academic client base. The key strategic objective of EuroSciCon is to communicate science and medical research between academia, clinical practice and the pharmaceutical industry. Most of its events are in Europe and London or live streamed. EuroSciCon expanded its operations to international in association with Meetings International, Singapore. All major meetings of EuroSciCon and Meetings International will issue Continued Professional Education (CPD), Continued Education (CE), Continued Medical Education (CME) Credits.